Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications
Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/7/1659 |
| _version_ | 1797433668524834816 |
|---|---|
| author | Yannick Simoni Nicolas Chapuis |
| author_facet | Yannick Simoni Nicolas Chapuis |
| author_sort | Yannick Simoni |
| collection | DOAJ |
| description | Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS will strongly increase in the future. Thus, precise diagnosis and evaluation of the progression risk of these diseases are imperative to adapt the treatment. Dysregulations of both innate and adaptive immune systems are frequently detected in MDS patients, and their critical role in MDS pathogenesis is now commonly accepted. However, different immune dysregulations and/or dysfunctions can be dynamically observed during the course of the disease. Monitoring the immune system therefore represents a new attractive tool for a more precise characterization of MDS at diagnosis and for identifying patients who may benefit from immunotherapy. We review here the current knowledge of the critical role of immune dysfunctions in both MDS and MDS precursor conditions and discuss the opportunities offered by the detection of these dysregulations for patient stratification. |
| first_indexed | 2024-03-09T10:20:16Z |
| format | Article |
| id | doaj.art-68003120520447bf93dc0f083e7513b0 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-09T10:20:16Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-68003120520447bf93dc0f083e7513b02023-12-01T22:04:03ZengMDPI AGDiagnostics2075-44182022-07-01127165910.3390/diagnostics12071659Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical ApplicationsYannick Simoni0Nicolas Chapuis1Institut Cochin, Université Paris Cité, CNRS UMR8104, INSERM U1016, 75014 Paris, FranceInstitut Cochin, Université Paris Cité, CNRS UMR8104, INSERM U1016, 75014 Paris, FranceMyelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS will strongly increase in the future. Thus, precise diagnosis and evaluation of the progression risk of these diseases are imperative to adapt the treatment. Dysregulations of both innate and adaptive immune systems are frequently detected in MDS patients, and their critical role in MDS pathogenesis is now commonly accepted. However, different immune dysregulations and/or dysfunctions can be dynamically observed during the course of the disease. Monitoring the immune system therefore represents a new attractive tool for a more precise characterization of MDS at diagnosis and for identifying patients who may benefit from immunotherapy. We review here the current knowledge of the critical role of immune dysfunctions in both MDS and MDS precursor conditions and discuss the opportunities offered by the detection of these dysregulations for patient stratification.https://www.mdpi.com/2075-4418/12/7/1659myelodysplastic syndromesclonal hematopoiesis of indeterminate potentialinflammationaginginnate immunityadaptive immunity |
| spellingShingle | Yannick Simoni Nicolas Chapuis Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications Diagnostics myelodysplastic syndromes clonal hematopoiesis of indeterminate potential inflammation aging innate immunity adaptive immunity |
| title | Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications |
| title_full | Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications |
| title_fullStr | Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications |
| title_full_unstemmed | Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications |
| title_short | Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications |
| title_sort | diagnosis of myelodysplastic syndromes from immunological observations to clinical applications |
| topic | myelodysplastic syndromes clonal hematopoiesis of indeterminate potential inflammation aging innate immunity adaptive immunity |
| url | https://www.mdpi.com/2075-4418/12/7/1659 |
| work_keys_str_mv | AT yannicksimoni diagnosisofmyelodysplasticsyndromesfromimmunologicalobservationstoclinicalapplications AT nicolaschapuis diagnosisofmyelodysplasticsyndromesfromimmunologicalobservationstoclinicalapplications |